Adam Grossman
Adam Grossman serves as the CEO, President, and Founder of ADMA Biologics, a role he has held since October 2011, having joined the company in 2007. With over 25 years of industry experience, he has been instrumental in transforming ADMA into a vertically integrated plasma products manufacturer, leading the company through significant growth, successful regulatory approvals, and over $1.2 billion in financing.
Career Milestones
- Adam Grossman founded ADMA Biologics in 2007, becoming President and CEO in October 2011.
- He led the company to go public in 2013 and secured FDA approvals for key products.
- In 2016, he was issued patents for ASCENIV™'s unique manufacturing methods.
- Grossman spearheaded the 2017 acquisition of Biotest Therapy Business Unit, transforming ADMA into a vertically integrated plasma products manufacturer.
- He has also completed over $1.2 billion in financing. These milestones underscore his commitment to addressing unmet medical needs for immune-compromised patients.
About ADMA Biologics
ADMA Biologics is a biopharmaceutical company that develops, manufactures, and commercializes plasma-derived biologics. They serve immune-compromised individuals and patients with immune deficiencies, focusing on addressing unmet medical needs in immunology and infectious diseases. Their differentiator lies in a vertically integrated business model, state-of-the-art facilities, and a strong emphasis on innovation and patient care, including the recent implementation of an AI program.